Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LK101 Injection in Advanced Solid Tumors
CTR20232018Phase 2Active
- Sponsor
- Likang Life Sciences
- Start
- Dec 2023
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LK101 in Nonhematologic neoplasms, sponsored by Likang Life Sciences. Started Dec 2023; status: active.
02
Drugs
LK101
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232018.